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Radiolabeled fragmented F(ab')2 antibodies had shown better therapeutic efficacy than radiolabeled intact antibodies in 
treating cancers.  In this study, we investigated the differences and similarities on the mechanism and extent of cell death in Raji 
cells (Burkitt’s lymphoma) in response to 370 kBq of 131I-F(ab')2-Rituximab and 
131I-Rituximab up to 72 h. F(ab')2 of Rituximab 
was prepared and characterized by SE-HPLC and SDS-PAGE. Fragmented and intact Rituximab were radioiodinated by 
Chloramine-T method. Toxicity and mechanism of cell death in Raji cells in response to 131I-F(ab')2-Rituximab and  
131I-Rituximab were studied by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), LDH (lactate 
dehydrogenase), trypan blue exclusion, viability, apoptotic, caspase assays and cell cycle analysis. The cytotoxicity assays 
showed slow death of Raji cells up to 24 h in response to both 131I-F(ab')2-Rituximab and 
131I-Rituximab. Cell cycle analysis at 
30 h showed G1 arrest in Raji cells which led to its slow cell death up to 24 h. Elucidative assays to identify the molecular 
mechanism of death of G1arrested Raji cells showed apoptotic cell death at 40 h after treatment, which was validated by 
demonstrating caspase activation in arrested Raji cells. Toxicity studies and mechanism of cell death in Raji cells demonstrated 
comparable results when treated with equivalent doses (370 kBq) of radiolabeled antibodies indicating 131I-F(ab')2-Rituximab as 
a potential radioimmunotherapeutic agent for patients with Non-Hodgkin’s lymphoma.  
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Rituximab (MabThera, Rituxan) is a chimeric IgG1 
monoclonal antibody that specifically targets the 
CD20 surface antigen expressed on normal and 
neoplastic B-lymphoid cells
1
. It is a FDA approved 
antibody that is widely used in the treatment of non-
Hodgkin’s Lymphoma [NHL]
2
. NHL constitutes 4% 
of all cancers and ranks as the 6
th
 most common 
cancer amongst females and the 7
th
 most common 
cancer in males
3
. The incidence rate of NHL 
estimated in India was 22 per million (23,801 new 
cases) with a mortality rate of 15 per million (16,597 
deaths) in 2012
4





I-Rituximab) is an useful radioimmunotherapeutic 
agent for NHL mainly due to its synergistic action of 
binding to specific tumor cells and β-radiations 
emitted by the 
131
I, both of which facilitate in the 




trials with  
131
I-Rituximab in patients with NHL have shown a 
good overall response with some patients even 
attaining complete response
6-8




(Bexxar), that targets CD20 antigen has shown 70 % 
response rate in the treatment of patients with 
NHL
9,10
. Radioiodinated Rituximab has also been 
used in combination therapy or as an adjunct therapy 
for achieving better therapeutic ratio in patients with 
NHL
11,12
. However, the main disadvantages of using 
intact antibodies are their slow pharmacokinetics, 
poor tumor penetration, lower target to non-target 
ratio and risk of humoral effect due to the large size 
(~150 Kd) and the Fc region, all of which can be 
overcome by use of fragmented antibodies [F(ab')2]
13
. 
Reports indicate that radiolabeled F(ab')2 promises to 
be a better theranostic agent as compared to intact 
antibody, when labeled with suitable theranostic 
radionuclides owing to its better pharmacokinetics, 
tumor penetration and high target to non-target ratio 
mainly due to its smaller size
14,15
. Various studies 
have reported that using radiolabeled F(ab')2 as a 
theranostic agent yielded promising results
16,17
. As a 
result of the faster pharmacokinetics of F(ab')2,  
131
I-F(ab')2 antibodies have exhibited better 
therapeutic effect than intact radiolabeled antibody  
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Further, increased dose of F(ab')2 fragments has 
shown to have enhanced therapeutic effect with no 
change in the minimal toxicity or normal tissue 
distribution pattern
18
.The rapid clearance of F(ab')2, 
allows delivery of twice the radiation dose to the 
tumor as compared to intact antibody, for the same 




In radioimmunotherapy (RIT), the radioimmuno-
conjugates kill cancer cells predominantly by 
radioactive emissions from the radionuclides rather 
than due to the immunological effector functions
22
. 
The most commonly used radionuclides for RIT  
(I-131, Lu-177 and Y-90) kill tumor cells primarily by 
emission of beta (β-) particles, which are considered 
to induce DNA strand breaks
23
. I-131 is one of the 
radionuclide of choice for RIT largely due to its easy 
availability, suitable half-life (8 days), β-emission 
(606 keV; 90 %) of relatively short path length and 
ease of radiolabeling of biomolecules
24
. I-131 also 
emits γ rays of 364 keV, which permits simultaneous 
imaging of radiolabeled product enabling study of its 




Studies on cellular toxicity and its molecular 





. Here, in order to evaluate 
the potential of 
131
I-F(ab')2-Rituximab as a radio-
immunotherapeutic agent for NHL, we carried out 
cytotoxicity studies, cellular arrest analysis, apoptosis 
and caspase assays in Raji cells in response to  







Materials and Methods 
 
Materials 
Rituximab (MabThera, antiCD20 monoclonal 
antibody) was procured from Roche Inc., Basel, 
Switzerland. Iodine-131 was produced in-house by (n, ) 
activation of tellurium oxide target and extracted by 
dry distillation technique. It was made available in the 





chemicals and reagents like MTT (3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide), sodium 
acetate, sodium chloride, sodium bicarbonate, 
HEPES, Roswell Park Memorial Institute medium 
(RPMI 1640) and trypan blue were procured from 
Sigma chemical Inc. (USA). Fetal Bovine Serum 
(FBS) was purchased from GIBCO Laboratories, 
USA. Assay kits for Cell cycle analysis, apoptosis, 
viability & caspase analyses were procured from 
Guava Technologies, Inc., Merck Millipore Corp., 
Germany. LDH assay kits were procured from Sigma 
chemical Inc. (USA). Immobilized Pepsin was 
obtained from Thermo Scientific while rProtein A 
Sepharose fast flow antibody affinity column and 
PD-10 columns were procured from GE Healthcare 
Life Sciences, USA. Protein molecular weight 
standards were procured from Bangalore Genei, India 
and /or GE Healthcare Ltd, UK and Amicon Ultra 
centrifugal filter devices (MW cut off 10 kDa and  
50 kDa) were from Millipore, India. Well type NaI 
(Tl) detector (ECIL, India) was used for measuring 
radioactivity. Size exclusion HPLC (SE-HPLC) 
analysis were performed on a JASCO HPLC system 
(M/s. JASCO, Japan) coupled to a NaI (Tl) radio-
activity detector (Raytest, Germany) and a PU 1575 UV/ 
visible detector (M/s. JASCO, Japan) using a TSK gel 
column (G3000 SWXL; 30 cm × 7.8 mm; 5 µm) from 
TOSOH Bioscience, USA. The chromatograms were 
assessed using the GINA STAR software (Version, 
M/s. Raytest GmBH, Germany). Guava EasyCyte 
Flow cytometer (Guava Technologies, Inc., Merck 
Millipore Corp. Germany) was used to acquire flow 
cytometry data and POLARstar Omega Plate Reader 
Spectrophotometer - BMG LABTECH, Germany was 
used to measure spectrometric reading. Raji cells 
(CD20 wildtype, Burkitt lymphoma cell line) were 





Preparation, Purification and Characterization of F(ab')2-
Rituximab 
Rituximab (MabThera, conc-10 mg/mL) was 
digested using bead immobilized pepsin in digestion 
buffer (20 mM sodium acetate solution, pH-4.5) at 
37°C for 18 h with continuous high speed shaking. 
The crude digest was purified using Amicon Ultra 
centrifugal filter devices (MW cut off 50000Da) and 
rProtein A Sepharose fast flow column sequentially. 
Flow through from Sepharose-rProtein A column was 
collected as 2 mL fractions which contained the 
purified F(ab')2 fragments. The F(ab')2 fragments were 
characterized by gradient SDS-PAGE (5-15 %) under 




Radioiodination and Characterization of F(ab')2-Rituximab & 
Rituximab  
Fragmented Rituximab (F(ab')2-Rituximab) and 
intact Rituximab were radioiodinated using the 
Chloramine-T method
30
. Briefly, to the reaction vial 
containing 200 μL of 0.5 M phosphate buffer, pH 7.6, 
F(ab')2-Rituximab (400 µg) or Rituximab (500 µg) 




and 1.5 mCi (55.5 MBq) of I-131 activity was added. 
This was followed by addition of 15 μL (~30 μg) of 
freshly prepared Chloramine-T in 0.05 M phosphate 
buffer, pH 7.4. After 90 s of reaction time, 45 μL  
(90 μg) of sodium metabisulphite in 0.05 M 
phosphate buffer, pH 7.4 was added, gently mixed 
and incubated for 60 s. The reaction was finally 
terminated with 100 μL (100 μg) of KI. The 
radiolabeled F(ab')2-Rituximab and Rituximab were 
purified by passing each through PD-10 desalting 
columns using 0.05 M phosphate buffer, pH 7.4  
for elution. Labeling efficiency and specific activity 






determined by SE-HPLC using a TSK gel column 
wherein elution was carried out isocratically with  
0.05 M phosphate buffer containing 0.05% sodium 
azide (pH 6.8) at a flow rate of 0.6 mL/min.  
 
In vitro cell Binding and Inhibition studies 





I- Rituximab were carried out in 
Raji cells that express CD20 on their cell surface. 
Cells were grown to 60-70% confluence in RPMI 
medium containing 10% FBS in a humidified CO2 
incubator at 37ºC. Cells were then harvested and 
1×10
6 
cells/well was layered in 12 well tissue culture 
plates. For cell binding studies, 1µg/mL of 
131
I-F(ab')2-
Rituximab and/or 1µg/mL of 
131
I-Rituximab were 
added and incubated for 2 h at 37ºC. All studies were 
carried out in triplicates. After incubation, the cells 
were washed twice with 1.0 mL of 0.05 M phosphate 
buffer saline (PBS) (pH 7.4) and centrifuged at  
2000 rpm for 20 min at room temperature (RT) of 
25°C. The supernatant was aspirated and the cell 
pellet measured for radioactivity.  
For inhibition studies, unlabeled Rituximab (10 µg 





assays were carried out under identical conditions as 
mentioned earlier. The percentage cell binding and 









In case of assays for cytotoxicity (MTT, LDH, 
trypan blue exclusion and viability assays), Raji cells 
were cultured in RPMI medium containing 10% FBS 
and grown up to 60-70% confluence. After harvesting, 
1×10
6
 cells were seeded in 12 well tissue culture plates 





I-Rituximab and incubated for 
various time intervals depending on the assay to be 
carried out. Concurrently, another set of cells were 
treated with equivalent amount of unlabeled F(ab')2-
Rituximab (2.7 µg) and Rituximab (3.3 µg) as 





I-Rituximab, respectively. Control set of cells 
were left untreated. All treatments were carried out in 
triplicates. 
 
MTT assay  
MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-
tetrazolium bromide) assay which is a colorimetric 
assay was used to measure cellular metabolic activity 
and hence the cell viability. Viable cells that contain 
NAD(P)H-dependent oxidoreductase enzymes reduce 
the MTT reagent to formazan, to give a deep purple 
colour
31




cells) of each 






F(ab')2-Rituximab and unlabeled Rituximab, was 
mixed with 50 µL of MTT solution (5 mg/mL in PBS) 
and incubated at 37°C for 3 h. After incubation, 150 µL 
of MTT solvent (4 mM HCl, 0.1% NP40 in isopropanol) 
was added and incubated for 15 min under shaking 
condition for dissolution of formazan. Reaction was 
stopped by adding 1/10 volume of 1N HCl and 
absorbance read at 590 nm. The % of dead cells was 
calculated as ([optical density (OD) of control sample 
- OD of treated sample/OD of control sample]*100). 
This was plotted against the different time points  
(8, 16, 24, 48 and 72 h) after treatment with the 





I-Rituximab, unlabeled F(ab')2-Rituximab 
and Rituximab]  
 
LDH assay 
Lactate Dehydrogenase (LDH) assay is a colorimetric 
assay to quantitatively measure LDH released into the 
media from damaged cells as a biomarker for cellular 
cytotoxicity and hence, a direct measure of the cell 
death. The procedure was carried out as per the 
reported protocol
27
. Herein, 100 µL of Raji cells 
(~1×10
5




I-Rituximab, unlabeled F(ab')2-Rituximab and 
unlabeled Rituximab were centrifuged at 8, 24, 48 and 
72 h post treatment and the supernatant was collected. 
This supernatant was mixed with LDH assay mixture 
(2:1, v/v) in 96 well plates and incubated at RT for  
25 min in dark. LDH assay mixture was made by 
mixing the dye with equal volumes of substrate and 
cofactor of LDH just before use. After incubation, the 




reaction was stopped by addition of 1/10 volume of  
1 N HCl and the absorbance measured at 490 nm. The 
% of dead cells represented as % release of LDH was 
calculated and plotted against different time points 
post treatment with the antibodies. 
 
Trypan Blue exclusion viability assay 
Additional viability assay i.e. trypan blue exclusion 
assay was carried out wherein the intact cells appear 
transparent while the dead cells take up the trypan 
blue dye and appear blue when viewed under the 
microscope. For this assay, 10 µL of 0.4% Trypan 
blue solution was mixed with 10 µL of the Raji cells 
(~1×10
4





Rituximab, unlabeled F(ab')2-Rituximab and 
Rituximab. The samples were counted for viability 
using a hemocytometer at 6, 16, 24, 48, and 72 h post 
treatment. The % dead cells was calculated and 
plotted as compared to the control cells at different 
time points post treatment.  
 
Viability assay 
Viability count assay was performed as per the 
procedure specified in the Guava ViaCount assay kit, 
Guava Technologies, Millipore. 50 µL of cell sample 
(~0.5×10
5 




I-Rituximab, unlabeled F(ab')2-Rituximab and 
Rituximab were mixed with 450 µL of Guava 
ViaCount reagent and incubated for 5 min at RT in 
dark. The viable count assay distinguishes the viable 
and non-viable cells based on the differential 
permeability’s of the two DNA-binding dyes. The 
nuclear dye stains only nucleated cells while the 
viability dye stains only the dead cells. Sample 
acquisition and data analysis were performed using 
the ViaCount software module in Guava EasyCyte 
Flow cytometer. The % dead cells as compared to 
control samples were calculated and plotted in 
response to the different treatments given at 24 and  
48 h post treatment.  
 
Cell cycle analysis 
Cell cycle analysis is based on the amounts of 
DNA present at different stages of the cell cycle, 
which is detected by the DNA-binding dye fixed on 
cells and acquired on a flow cytometer. In order to 
investigate the slow death up to 24 h, cell cycle analysis 






F(ab')2-Rituximab and Rituximab. Raji cells were 
processed as per the procedure given in Guava cell 
cycle kit. Briefly, the cells (~1×10
6
 cells) were washed 
with PBS (0.05 M, pH 7.4) and fixed in 70% ice-cold 
ethanol. The cells were kept at 4ºC for 1 h prior for 
staining. Herein, ethanol was completely removed 
from the cell suspension by repeated washes with 0.05 M 
PBS, pH 7.4, resuspended in 200 µL Guava cell cycle 
reagent and incubated for 30 min at RT in dark. Sample 
data were acquired using the Cell Cycle software 
module in Guava EasyCyte Flow cytometer and 
analyzed using Cyflogic software. The percentage of 
cells acquired from the treated groups as compared to 
the control at different stages of cell cycle were 
analyzed and plotted for the different treatments given. 
 
Apoptotic assay 
Apoptotic assay was performed to determine the 
mode of death of the arrested Raji cells. The cell 





Rituximab, unlabeled F(ab')2-Rituximab and 
rituximab were processed at 40 h post treatment as per 
the protocol specified in the Guava Apoptotic kit. 
Briefly, 100 µL of treated cell samples were mixed 
with 100 µL of Guava annexin reagent and incubated 
for 20 min at RT in dark. Nexin reagent contains 
annexin V-PE that binds to phosphatidyl serine (PS) 
which is an indicator of apoptosis. Nexin reagent also 
contains a cell impermeant DNA binding dye 7-AAD 
(7-aminoactinomycin D) which determines the 
membrane integrity. Sample acquisition and data 
analysis were performed using the Nexin software 
module in Guava EasyCyte Flow cytometer. The % of 
cells in early to mid stages of apoptosis were 




Caspase assay was carried out to check the caspase 
activation for validation of apoptotic death of arrested 
Raji cells in G1 stage. Activation of Capase 3 and 7 
was determined using the Guava Easy Cyte caspase 
3/7 kit. This kit uses a FLICA (Fluorescent labeled 
inhibitor of Caspases) consisting of 3 subunits - an 
amino acid inhibitor sequence recognized by caspase 
3/7 aspartic acid-glutamic acid-valine-aspartic acid 
(DEVD), a fluoromethyl ketone moiety which 
covalently binds active caspase 3/7 enzymes and a 
carboxyfluorescein (FAM) reporter. Unbound FLICA 
diffuses out of cell while FLICA positive cells 
(Caspase +) correspond to apoptotic cells. The cell 
impermeant DNA binding dye 7-AAD (7-amino-
actinomycin D) permits simultaneous evaluation of 







F(ab')2-Rituximab and Rituximab treated cell samples 




were processed as per the procedure given in the 
Guava caspase kit, Guava Technologies, Millipore. 
Briefly, 100 µL of treated cell samples  
(~1×10
5
 cells) were mixed with 10 µL of caspase 
reagent solution and incubated for 1 h at 37°C in a 
CO2 incubator. The cells were washed twice with 1X 
apoptosis wash buffer and incubated with 200 µL of 
caspase 7-AAD working solution for 10 min at RT. 
Sample acquisition and data analysis were carried out 
using the Caspase software module in Guava 
EasyCyte Flow cytometer. The % of treated cells 
showing caspase activation as compared to control 
samples were analyzed at 40 h post treatment and 
plotted for the different treatments given. 
 
Statistical analysis 
All experiments are performed in triplicates. 
Results given are mean ± standard error of at least  
3 independent experiments. All statistical analyses 
were performed using the one-way analysis of 
variance (ANOVA) followed by Post-hoc Bonferroni 
test to compare between different pair of treatments 
for determining the significance value. P ≤0.05 was 




Preparation, purification and characterization of (Fab’)2 of 
Rituximab 
Standardization experiments revealed that in order 
to achieve maximum digestion, the optimum time for 
digestion of Rituximab with pepsin was 18 h. From 
10 mg of Rituximab originally taken for digestion, 
7.86 mg F(ab')2-Rituximab (78.6%) was obtained. 
Purified F(ab')2-Rituximab was characterized by SDS-
PAGE under non-reducing and reducing conditions. 
Under non-reducing conditions, the purified F(ab')2-
Rituximab exhibited a molecular weight of ~100 kDa 
by SDS-PAGE (Fig. 1A), while under reducing 
conditions, the heavy and light chain bands were 
observed at ~29 and ~25 kDa, respectively (Fig. 1B).  
 
Radioiodination of F(ab')2 of Rituximab/Intact Rituximab and 
their characterization 
The labeling efficiency of radioiodination of 
F(ab')2-Rituximab and Rituximab was 92-93 %  
while the specific activity was determined to be  
136.9 kBq/µg for F(ab')2-Rituximab and 111 kBq/µg 




I-Rituximab showed a 
single peak with retention times of 15.34 min and 
14.51 min, respectively which corresponded to the 
unlabeled counterparts (Fig. 2 A and B). 
Cell binding and inhibition studies 





I-Rituximab in Raji 
cells to determine their specificity to the CD20 




Fig. 1 — SDS-PAGE on 5-15% gradient gel. (A) Under non-
reducing conditions - (Lane 1: Protein molecular weight standards, 
Lane 2: Intact Rituximab (15 µg), Lane 3: F(ab')2 of Rituximab 
(20µg), Lane 4: F(ab')2 of Rituximab (40µg); (B) Under reducing 
conditions using -mercaptoethanol - (Lane1: Protein molecular 
weight standards (GE Healthcare), Lane 2: Intact Rituximb  
(15 µg), Lane 3: F(ab')2 of Rituximab (20 µg), Lane 4: Protein 





Fig. 2 — Size exclusion HPLC chromatogram of (A) 131I-
Rituximab; and (B) 131I-F(ab')2-Rituximab on a TSK gel column 
by isocratic elution with 0.05 M phosphate buffer + 0.05% sodium 
azide (pH 6.8) at 0.6 mL/min. [RCP of radioimmunoconjugates > 
95%; (Rt of 
131I-Rituximab=14.51 min; Rt of 
131I-F(ab')2-
Rituximab =15.34 min)] 
 





I-F(ab')2-Rituximab showed a binding of 
12.9±1.3% which was comparable to the binding 
exhibited by 
131
I-Rituximab of 12.2±0.6%; (P ≤0.05). 
Similarly, inhibition studies with 10 µg and 50 µg of 






indicating that the specificity of F(ab')2-Rituximab or 
intact Rituximab to the CD20 antigen was retained 
after radioiodination. Inhibitions of 21.7% and 26.4 % 
were observed when 
131
I-F(ab')2-Rituximab was  
co-incubated with 10 µg and 50 µg of unlabeled 
Rituximab, respectively while the inhibitions were  
14 and 18% when 
131
I-Rituximab was co-incubated 
with 10 µg and 50 µg of unlabeled Rituximab, 
respectively (Fig. 3). 
 
Cytotoxicity studies 
The extent of death of Raji cells in response to  





was determined to be similar (P <0.05) by the different 
cytotoxicity assays performed. A 2-3 fold higher 
cytotoxicity was observed when the cells were treated 
with 
131
I-F(ab')2-Rituximab and /or 
131
I- Rituximab as 
compared to their unlabeled vehicle controls. 
 
MTT assay 
MTT assay directly correlates with the cell 





F(ab')2-Rituximab and Rituximab were compared with 
the untreated control cells at different time points up 
to 72 h. The % cell death compared to untreated 
control was plotted against the different time points 
studied post treatment as indicated in Fig. 4A. It is 






comparable and not statistically different (P <0.05). 
Moreover, the % cell death was 2-3 fold higher in 





I-Rituximab as compared to cells treated with 




LDH released from damaged cell is a direct 
measure of cytotoxicity. The % cell death of Raji cells 





Rituximab, unlabeled F(ab')2 and Rituximab were 
compared with the untreated control Raji cells and 
plotted against the time points post treatment. As 





12.9±1.08 and 15.4±0.4%, respectively at 8 h. which 
increased to 97.3±1.3 and 95.3±1.02% at 72 h, 






was determined to be comparable (P <0.05) and more 
than 2-3 fold as compared to unlabeled F(ab')2-





Fig. 3 — Cell binding studies with 131I-Rituximab & 131I-F(ab')2-






Fig. 4 — Scatter plot of the cytotoxicity assays - (A) MTT assay; (B) LDH assay; (C) Trypan Blue exclusion viability assay; and (D) 
histogram plot of viability assay showing % cell death in response to 131I-F(ab')2-Rituximab, 
131I-Rituximab, unlabeled F(ab')2-
Rituximab and Rituximab as compared to untreated control cells at different time points post treatment 
 




Trypan Blue exclusion viability assay 
In the Trypan blue assay, the transparent viable 
cells and blue stained non-viable cells were counted. 






Rituimab and Rituximab compared to untreated 
control cells were plotted against different time points 
post treatment (Fig. 4C). Here again, a comparable 






(P <0.05) which was 2-3 fold higher when treated 
with unlabeled F(ab')2-Rituximab and Rituximab at 
different time points. 
 
Viability assay 






unlabeled F(ab')2-Rituximab and Rituximab in the 
sample. The % cell death of treated Raji cells as 
compare to untreated control cells at 24 h and 48 h 
post treatment were calculated and plotted as 
indicated in Figure 4d. It is evident that the extent of 





I-Rituximab are similar (P <0.05) and 2-3 fold 
higher than that exhibited by their unlabeled 
counterparts at 24 and 48 h. 
 
Cell cycle analysis 
To investigate the comparatively slow death of Raji 
cells up to 24 h, cell cycle analysis of treated Raji 
cells was carried out at 30 h. Fig. 5 (A-E) represents 
the cell cycle data as analyzed by Cyflogic software. 
The % of cells at different stages of cell cycle was 
compared between the different treatments given, 
which indicated that Raji cells were arrested in G1 
stage of the cell cycle. The % of cells in the G1 stage 
were calculated and plotted as compared to untreated 
control cells in response to different treatments.  
Fig. 5F is the graphical representation of the % of 
cells which are in G1 stage as compared to untreated 
control cells. This was determined to be 7.4±0.6 and 
9.9±2.0% in response to F(ab')2-Rituximab and 
Rituximab, respectively while it was 35.6±7.2 and 




I-Rituximab, respectively. These results are 




Fig. 5 — Flow cytometry cell cycle analysis: (A) untreated control Raji cells. Cell cycle progress in Raji cells in response to treatment 
with (B) unlabeled Rituximab; (C) unlabeled F(ab')2-Rituximab; (D) 
131I-Rituximab; (E) 131I-F(ab')2-Rituximab; and (F) Histogram 
representation of the number of Raji cells in G0/G1stage compared to untreated control cells. [This plot was obtained from the data of 
(A) to (E) undoubtedly indicating G0/G1 arrest of Raji cells in response to the various treatments given] 





To determine the mode of death of the arrested Raji 
cells, apoptosis assay was performed at 40 h.  
Fig. 6 (A-E) represents the apoptotic data acquired by 
Nexin software module in Guava EasyCyte Flow 
cytometer. Lower-right side quadrant of the double 
plot represents % of cells in early to mid stage of 
apoptosis. Fig. 6F is the graphical representation of 
the % of cells undergoing apoptotic death as 
compared to untreated control cells. This was 
calculated and plotted in response to different 
treatments given. It was observed that the % of cells 
in early to mid stage of apoptosis compared to 





I-Rituximab was 372.5±12.7 and 357.6±12.3%, 






were comparable and not significantly different  
(P <0.05). These results indicated that one of the 
modes of the death in arrested Raji cells in G1 stage 
were by apoptosis.  
 
Caspase assay 
Apoptotic death was validated by demonstrating 
caspase 3 and 7 activation using caspase assay in the 
arrested Raji cells at 40 h. Fig. 7 (A-E) illustrates the 
typical data of caspase activation acquired in by 
Caspase software in Guava EasyCyte Flow cytometer. 
Lower and upper right side quadrants of the double 
plot depict the cells having active caspase activity. 
The % of cells showing caspase activation as compared 
to untreated control cells were calculated and plotted 
in response to different treatments given (Fig.. 7F). 
The results showed that 181.6±0.1 and 161.8±2.3% of 
the cells have caspase activation (caspase +) as 





I- Rituximab, respectively. On 
the other hand, the % of cells that have caspase 




Fig. 6 — Flow cytometry analysis of annexin-V and 7-AAD (7-Aminoactinomycin D) staining of apoptotic cells of Raji cells. (A) 
untreated control Raji cells. Raji cells in response to treatment with (B) unlabeled Rituximab; (C) unlabeled F(ab')2-Rituximab; (D) 
131I-
Rituximab; (E) 131I-F(ab')2-Rituximab; and (F) Histogram representation of the % of apoptotic cells compared to untreated control cells 
in response to the different treatments given 
 




control cells in response to unlabeled F(ab')2-
Rituximab and unlabeled Rituximab was 91.8±8.4 
and 99.3±0.6%, respectively. 
 
Discussion  
Longer circulation time, non-specific binding and 
formation of immune responses have limited the 
utilization of monoclonal antibody in clinical 
oncology. F(ab')2 of antibody has added advantages of 
faster pharmacokinetics, rapid clearance from body, 
high tumor / blood ratio, favorable imaging kinetics, 
better tumor penetration, lower immunogenicity 
potential and low non-specific binding largely due to 
its smaller size and absence of the Fc region as 
compared to the intact antibody
13
. Another therapeutic 
advantage of F(ab')2 over intact monoclonal antibody 
is its minimal toxicity to organs due to its rapid 
clearance, thereby permitting administration of 
multiple doses and demonstration of high tumor/non-
tumor uptake after treatment
18,32
. Hence, F(ab')2 of 
antibody are more preferred for radioimmunotherapy 
and radioimmunoscintigraphy. F(ab')2 has been used 
for improved radioimaging, tumor localization and 
scintigraphy of colorectal carcimoma
33,34
. Clinical 
trials using F(ab')2-antibodies for radioimmuno-
therapy of metastatic colorectal cancer, gastro-
intestinal cancer and patients with glioblastomas have 






Fig. 7 — Flow cytometry analysis (A-E) for caspase 3 and 7 activation to validate apoptotic death in Raji cells at 40 h post treatment. (A) 
untreated control Raji cells. Raji cells in response to treatment with (B) unlabeled Rituximab; (C) unlabeled F(ab')2-Rituximab; (D) 
131I-
Rituximab; (E) 131I-F(ab')2-Rituximab; and (F) demonstrates caspase 3 and 7 activation in Raji cells compared to untreated control cells 
at 40 h in response to the different treatments given 
 




The present study was aimed at studying the 
cytotoxicity and mechanism of cell death in Raji cells 
in response to 
131
I-F(ab')2-Rituximab. This would 
provide insight of the feasibility of using 
131
I-F(ab')2-
Rituximab as a radioimmunodiagnostic and radio-
immunotherapeutic agent for NHL. Hence, a 
comparative study on the cytotoxicity and molecular 
mechanism of cell death in Raji cells was carried out 











comparable extent of toxicity at different time points 
studied i.e. 8, 16, 24, 48 , and 72 h post treatment. 




I-Rituximab in Raji cells 
as compared to Raji cells treated with unlabeled 
F(ab')2-Rituximab and Rituximab. Reports revealed 
similar results wherein Raji cells treated with 
131
I-
Rituximab (1.85 MBq for 2 h) had significantly 
higher toxicity (~2-2.5 fold higher) at 24 h as 
compared to cells treated with the same concentration 
of unlabeled Rituximab
27
. Raji cells treated with 
131
I-
Rituximab for 2 h with 1.85 MBq exhibited ~22% cell 






significantly higher growth inhibition rate of the cells 
as compared to unlabeled Rituximab (P ≤0.05) at a 
specific activity of 60 µCi/mL
26
. The comparable 





I-Rituximab favours the use of 
131
I-
F(ab')2-Rituximab as an effective radioimmuno-
conjugate with its added attributes, for both diagnosis 
and treatment of NHL. 
In this study, Raji cells showed G1 arrest at 30 h 






Similar studies showed that majority of the Raji cells 




. The apoptotic rate in these Raji cells 
were 51.99% in 
131
I-Rituximab group, 29.42% in 
Rituximab group and 26.17% in the untreated control 
group
36
. In an another study, Raji cells when treated 
with 
131
I-Rituximab (1.85 MBq for 2 h) showed ~2.5 
fold at 2-8 h and ~25 fold at 24 h higher apoptosis as 
compared to untreated control Raji cells
5,27
. On the 
other hand, Raji cells treated with unlabeled 
Rituximab showed ~2.5 fold at 2 h and ~4 fold at 24 h 
higher apoptosis, as compared to untreated control 
cells
5,27




I-Rituximab may have 
similar cytotoxicity in vivo as well. Further, animal 
studies are essential to study the cytotoxicity of  
131
I-F(ab')2-Rituximab in vivo, its degree of tumor 
penetration and target to non-target ratio as compared 
to 
131
I-Rituximab to confirm its utility as a good 
radioimmunotherapeutic agent for NHL. 
 
Conclusion 
Results of this study advocate the use of 
fragmented antibody (
131
I-F(ab')2-Rituximab) as a 
radioimmunotherapeutic agent as it has shown 
comparable degree of cytotoxicity and similar 
mechanism of cell death in vitro in Raji cells when 
compared with intact Rituximab (
131
I-Rituximab). 
This study would help in realizing the potential of 
131
I-F(ab')2-Rituximab as an efficient radioimmuno-
therapeutic agent for NHL. However, biodistribution 
and pharmacokinetic studies of 
131
I-F(ab')2-Rituximab 
in tumor model studies are warranted to confirm the 
same in vivo. 
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